Study on the Association of Synergistic Effects of Wuzhi Capsules on Tacrolimus with CYP3A5*3 Gene Polymorphism
	    		
		   		
		   			
		   		
	    	
    	 
    	10.6039/j.issn.1001-0408.2017.05.02
   		
        
        	
        		- VernacularTitle:五酯胶囊对他克莫司增效作用与CYP3A5*3基因多态性的相关性研究
 
        	
        	
        	
        		- Author:
	        		
		        		
		        		
			        		Yan YANG
			        		
			        		;
		        		
		        		
		        		
			        		Huawen XIN
			        		
			        		;
		        		
		        		
		        		
			        		Fei LIU
			        		
			        		;
		        		
		        		
		        		
			        		Lei XIONG
			        		
			        		;
		        		
		        		
		        		
			        		Weiliang LI
			        		
			        		;
		        		
		        		
		        		
			        		Airong YU
			        		
			        		
		        		
		        		
		        		
		        		
		        		
			        		
			        		
		        		
	        		
        		 
        	
        	
        	
        	
        		- Keywords:
        			
	        			
	        				
	        				
			        		
				        		CYP3A5*3;
			        		
			        		
			        		
				        		Gene polymorphism;
			        		
			        		
			        		
				        		Wuzhi capsules;
			        		
			        		
			        		
				        		Tacrolimus;
			        		
			        		
			        		
				        		Synergistic effects
			        		
			        		
	        			
        			
        		
 
        	
            
            
            	- From:
	            		
	            			China Pharmacy
	            		
	            		 2017;28(5):581-585
	            	
            	
 
            
            
            	- CountryChina
 
            
            
            	- Language:Chinese
 
            
            
            	- 
		        	Abstract:
			       	
			       		
				        
				        	OBJECTIVE:To investigate the association of synergistic effects of Wuzhi capsules on tacrolimus with CYP3A5*3 (6986A>G,rs776746) gene polymorphisms. METHODS:One hundred and severty patients underwent renal transplantation receiving tacrolimus maintenance therapy after surgery were selected from our hospital during Jan. 1997-Dec. 2015,and then divided into Wuzhi capsules(+)group(74 cases)and Wuzhi capsules(-)group(96 cases)according to the use of Wuzhi capsules. Both groups received tacrolimus+mycophenolate mofetil+prednisone;Wuzhi capsules (+)group was additionally given Wuzhi capsules,one capsule each time,bid,for more than 12 months. Trough concentration of tacrolimus was detected by CMIA 0,1,3,6,12 months after medica-tion,and the blood concentrations(C0/D)were calculated at different time points after correcting daily dose. CYP3A5*3 gene polymor-phisms was detected by PCR-RFLP. The association of C0/D value with gene polymorphism was investigated by analysis of covariance. RESULTS:Among 170 patients,there were 65 cases of CYP3A5 GG genotype,83 cases of AG genotype and 22 cases of AA geno-type;genotype frequencies were 38.2%,48.8% and 12.9%,which was in line with Hardy-Weinberg balance (P>0.05). There was statistical significance in the distribution frequencies of GG,AG+AA genotype between Wuzhi capsules(+)group and Wuzhi capsules (-)group (P<0.05). After 1 month of medication,C0/D of tacrolimus in GG genotype was significantly higher in Wuzhi capsules (+)group than in Wuzhi capsules(-)group. After 1,3,6,12 months of medication,C0/D of tacrolimus in AG+AA genotype was sig-nificantly higher in Wuzhi capsules(+)group than in Wuzhi capsules(-)group,with statistical significance(P<0.05). There was no statistical significance in C0/D of tacrolimus in GG genotype between 2 groups after 3,6,12 months of treatment(P>0.05). CON-CLUSIONS:Wuzhi capsules can increase C0/D of tacrolimus in CYP3A5*3 AG+AA genotype,but have no significant effect on C0/D of tacrolimus in GG genotype;CYP3A5*3 genotype should be considered when using Wuzhi capsules as synergist of tacrolimus.